OVERVIEW

Live Q&A: Today and Tomorrow: Managing Resistance in Heavily ART-Experienced People with HIV is organized by CME Outfitters, LLC.

Premiere Date: Friday, December 9, 2022
Credit Expiration Date: Saturday, December 9, 2023

Description:
The use of antiretroviral (ARV) medication therapies has led to successful treatment for many patients with HIV. However, antiretroviral therapy (ART) resistance and treatment medication adherence problems reduce the chances of success.1,2 Healthcare professionals (HCPs) need up-to-date education on the causes of ART resistance and non-adherence issues for patients who are treatment-experienced, as well as the treatment alternatives available including new ARV therapies with varying mechanisms of delivery (e.g., oral vs. injections). With this education, HCPs will be better prepared to treat patients with HIV who are treatment-experienced, reducing or mitigating the problems of ART treatment resistance and medication non-adherence.

• World Health Organization (WHO). WHO fact sheet: HIV drug resistance. WHO Website. https://www.who.int/news-room/fact-sheets/detail/hiv-drug-resistance. Published November 18, 2020. Accessed June 2, 2021.
• Benson C, Wang X, Dunn, KJ, et al. Antiretroviral adherence, drug resistance, and the impact of social determinants of health in HIV-1 patients in the US. AIDS Behav. 2020;24(12):3562-3573.

Learning Objectives:
At the end of this CME/CE activity, participants should be able to:
• Identify the etiology of ARV treatment resistance to improve HCPs’ competence in assessing and managing HIV in individuals who are heavily treatment-experienced.
• Apply efficacy and safety data for current and new ARV treatments that minimize the risk of treatment resistance in treatment-experienced patients with HIV.
• Evaluate efficacy and safety data for new and emerging long-acting oral and injectable ART regimens for heavily treatment-experienced people with HIV, including individuals with ARV resistance.